Kazia Therapeutics Limited is a biotechnology business based in the US. Kazia Therapeutics shares (KZIA) are listed on the NASDAQ and all prices are listed in US Dollars.
How to buy shares in Kazia Therapeutics
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – KZIA – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
Kazia Therapeutics stock price (NASDAQ: KZIA)Use our graph to track the performance of KZIA stocks over time.
Kazia Therapeutics shares at a glance
|Latest market close||$9.51|
|52-week range||$3.82 - $15.85|
|50-day moving average||$9.86|
|200-day moving average||$10.41|
|Wall St. target price||$17.02|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.92|
Buy Kazia Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Kazia Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Kazia Therapeutics price performance over time
|1 week (2021-07-19)||N/A|
|1 month (2021-06-30)||-3.55%|
|3 months (2021-04-30)||-11.45%|
|6 months (2021-01-26)||N/A|
|1 year (2020-07-26)||N/A|
|2 years (2019-07-26)||N/A|
|3 years (2018-07-26)||N/A|
|5 years (2016-07-26)||N/A|
Kazia Therapeutics financials
|Gross profit TTM||$988,000|
|Return on assets TTM||-26.94%|
|Return on equity TTM||-58.95%|
|Market capitalisation||$129.3 million|
TTM: trailing 12 months
Shorting Kazia Therapeutics shares
There are currently 27,916 Kazia Therapeutics shares held short by investors – that's known as Kazia Therapeutics's "short interest". This figure is 58.1% up from 17,654 last month.
There are a few different ways that this level of interest in shorting Kazia Therapeutics shares can be evaluated.
Kazia Therapeutics's "short interest ratio" (SIR)
Kazia Therapeutics's "short interest ratio" (SIR) is the quantity of Kazia Therapeutics shares currently shorted divided by the average quantity of Kazia Therapeutics shares traded daily (recently around 54737.254901961). Kazia Therapeutics's SIR currently stands at 0.51. In other words for every 100,000 Kazia Therapeutics shares traded daily on the market, roughly 510 shares are currently held short.
However Kazia Therapeutics's short interest can also be evaluated against the total number of Kazia Therapeutics shares, or, against the total number of tradable Kazia Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Kazia Therapeutics's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Kazia Therapeutics shares in existence, roughly 0 shares are currently held short) or 0.003% of the tradable shares (for every 100,000 tradable Kazia Therapeutics shares, roughly 3 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Kazia Therapeutics.
Find out more about how you can short Kazia Therapeutics stock.
Kazia Therapeutics share dividends
We're not expecting Kazia Therapeutics to pay a dividend over the next 12 months.
Have Kazia Therapeutics's shares ever split?
Kazia Therapeutics's shares were split on a 1:4 basis on 13 July 2017. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Kazia Therapeutics shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Kazia Therapeutics shares which in turn could have impacted Kazia Therapeutics's share price.
Kazia Therapeutics share price volatility
Over the last 12 months, Kazia Therapeutics's shares have ranged in value from as little as $3.816 up to $15.85. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kazia Therapeutics's is 2.7003. This would suggest that Kazia Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Kazia Therapeutics overview
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. It has collaboration agreements with St Jude Children's Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and the University of Newcastle. Kazia Therapeutics Limited also has collaboration with Dana-Farber Cancer Institute to investigate the use of Kazia's investigational new drug paxalisib in primary central nervous system lymphoma; Kintara Therapeutics, Inc. for the activation of paxalisib and VAL-083; and Joan & Sanford I Weill Medical College of Cornell University for Phase II clinical study using Paxalisib in combination with ketogenic diet for glioblastoma. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017.
Kazia Therapeutics in the news
Kazia Calls for Increased Focus on Brain Cancer Research this GBM Awareness Day
Kazia Calls for Increased Focus on Brain Cancer Research this GBM Awareness Day
EXECUTIVE CHANGES: AB Dynamics founder retires; Resolute hires CFO
Frequently asked questionsWhat percentage of Kazia Therapeutics is owned by institutions?
Currently 4.241% of Kazia Therapeutics shares are held by institutions. When does the fiscal year end for Kazia Therapeutics?
Kazia Therapeutics's fiscal year ends in June. Where is Kazia Therapeutics based?
Kazia Therapeutics's address is: Three International Towers, Sydney, NSW, Australia, 2000 What is Kazia Therapeutics's ISIN number?
Kazia Therapeutics's international securities identification number is: US48669G1058 What is Kazia Therapeutics's CUSIP number?
Kazia Therapeutics's Committee on Uniform Securities Identification Procedures number is: 48669G105
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert